SPRIM Global Investments

SPRIM sources deals primarily through the advisory relationships of its parent consultancy, the SPRIM group. The consultancy works with large pharmaceutical, medtech, and healthcare organizations, giving the investment team early visibility into emerging technologies and companies navigating clinical validation or regulatory approval. This proprietary flow often means SPRIM enters cap tables before companies run formal venture fundraises.

SPRIM Global Investments focuses primarily on venture-stage companies in life sciences, digital health, and health technology. Its portfolio emphasizes sectors with significant regulatory barriers — medical devices, diagnostics, and therapeutic platforms. The firm invests directly and occasionally co-invests alongside other venture funds, with a geographic focus on the US, Europe, and Singapore.

SPRIM Global Investments selectively co-invests alongside other venture capital firms, particularly those active in European and Asian health-tech. The firm has participated in syndicated rounds for companies such as Biotia and several digital therapeutic platforms. Its co-investment approach is deal-specific rather than programmatic, reflecting the negotiated nature of opportunities that emerge from its advisory relationships.